论文部分内容阅读
目的探讨新辅助化疗对结直肠癌肝脏转移瘤肝切除术后的影响。方法结直肠癌肝脏转移瘤患者57例,分为术前行新辅助化疗组(A组)23例和直接手术组(B组)34例,对比分析其疗效。结果两组均无手术30 d内死亡病例。其中输血人数、住院天数、胆漏在A组明显高于B组,差异均有统计学意义(均P<0.05)。呼吸系统并发症、循环系统并发症,两组差异均无统计学意义(均P>0.05)。1、3、5年生存率A组分别为:83.3%,60.2%,37.5%,而B组分别为84.8%,68.2%,32.5%,两组差异均无统计学意义(均P>0.05)。结论术前评估肝脏转移瘤可切除的患者,如无明显手术禁忌症可直接手术治疗,这样可减少相应的术后并发症。
Objective To investigate the effect of neoadjuvant chemotherapy on liver metastases of colorectal cancer after liver resection. Methods 57 patients with metastatic liver cancer of colorectal cancer were divided into preoperative neoadjuvant chemotherapy group (A group), 23 cases and direct surgery group (B group), 34 cases were compared and analyzed. Results There was no death within 30 days in both groups. The number of blood transfusion, hospital stay and bile leakage were significantly higher in group A than in group B (all P <0.05). Respiratory complications and circulatory complications were not statistically different between the two groups (all P> 0.05). The 1-year, 3-year and 5-year survival rates in group A were 83.3%, 60.2% and 37.5%, respectively, while those in group B were 84.8%, 68.2% and 32.5% respectively. There was no significant difference between the two groups (all P> 0.05) . Conclusions Patients with resectable liver metastases before surgery can be directly surgically treated without obvious surgical contraindications, which can reduce the corresponding postoperative complications.